Jeffrey C. Thompson

3.7k citations

60 papers · 1.4k indexed · 1 hit paper · h-index 18

Oncology top 5%
Pulmonary and Respiratory Medicine top 5%
Cancer Research top 10%
Immunology top 10%
Molecular Biology

Co-authors: Charu Aggarwal Corey J. Langer Joshua Bauml Roger B. Cohen Robert Broadwater Christine Ciunci Stephen Bagley Erica L. Carpenter
Topics: Lung Cancer Treatments and Mutations (18 papers)Cancer Immunotherapy and Biomarkers (15 papers)Cancer Genomics and Diagnostics (14 papers)
Cited by: Oncology Cancer Research Pulmonary and Respiratory Medicine
Journals: Journal of Clinical Oncology Blood Cancer Research
Partner nations: United States United Kingdom Austria

In The Last Decade

Jeffrey C. Thompson

57 papers receiving 1.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer

2017 387 citations Stephen Bagley, Shawn Kothari et al. Lung Cancer profile →

Peers

Countries citing papers authored by Jeffrey C. Thompson

Since Specialization

Citations

This map shows the geographic impact of Jeffrey C. Thompson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jeffrey C. Thompson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jeffrey C. Thompson more than expected).

Fields of papers citing papers by Jeffrey C. Thompson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jeffrey C. Thompson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jeffrey C. Thompson. The network helps show where Jeffrey C. Thompson may publish in the future.

Co-authorship network of co-authors of Jeffrey C. Thompson

This figure shows the co-authorship network connecting the top 25 collaborators of Jeffrey C. Thompson. A scholar is included among the top collaborators of Jeffrey C. Thompson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jeffrey C. Thompson. Jeffrey C. Thompson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Predictive Signatures for Responses to Checkpoint Blockade in Small-Cell Lung Cancer in Second-Line Therapy Do Not Predict Responses in First-Line Patients 2024 ·Cancers ·Jeffrey C. Thompson,Caitlin M. Tilsed,Christiana Davis,(unknown),(unknown),(unknown),Michael E. Kallen,Cynthia Timmers,Corey J. Langer,Steven M. Albelda	1
2	Red blood cells function as reservoirs of tumor DNA 2024 ·American Journal of Physiology-Lung Cellular and Molecular Physiology ·Jeffrey C. Thompson,(unknown),(unknown),Jarrod D. Predina,(unknown),Evgeniy Eruslanov,Sunil Singhal,Steven Μ. Albelda,Nilam S. Mangalmurti	2
3	Elucidating the influences of social determinants of health on perceived overall health among African American/Black and Hispanic ovarian cancer survivors using the NIH All of Us Research Program 2024 ·Gynecologic Oncology ·(unknown),R Mukherjee,Jeffrey C. Thompson	1
4	Association Between Availability of Molecular Genotyping Results and Overall Survival in Patients With Advanced Nonsquamous Non–Small-Cell Lung Cancer 2023 ·JCO Precision Oncology ·Charu Aggarwal,Melina E. Marmarelis,Wei‐Ting Hwang,(unknown),(unknown),Aditi P. Singh,Lova Sun,John A. Kosteva,(unknown),Roger B. Cohen,Corey J. Langer,Abigail Doucette,Peter Gabriel,Lawrence N. Shulman,Katharine A. Rendle,Jeffrey C. Thompson,Justin E. Bekelman,Erica L. Carpenter	22
5	Patterns of Failure in Metastatic NSCLC Treated With First Line Pembrolizumab and Use of Local Therapy in Patients With Oligoprogression 2023 ·Clinical Lung Cancer ·(unknown),Nikhil Yegya‐Raman,Siqi Zhang,(unknown),Roger B. Cohen,Charu Aggarwal,Jeffrey C. Thompson,Melina E. Marmarelis,William P. Levin,Keith A. Cengel,Christine Ciunci,Aditi P. Singh,Christopher D’Avella,Christiana Davis,Corey J. Langer,Steven J. Feigenberg	7
6	Molecular response assessment using circulating tumor DNA (ctDNA) in advanced solid tumors 2023 ·British Journal of Cancer ·Jeffrey C. Thompson,(unknown),Erica L. Carpenter,Charu Aggarwal	35
7	Impact of Interobserver Variability in Manual Segmentation of Non-Small Cell Lung Cancer (NSCLC) Applying Low-Rank Radiomic Representation on Computed Tomography 2021 ·Cancers ·(unknown),Bardia Yousefi,(unknown),Maya Galperin-Aizenberg,Leonid Roshkovan,José Marcio Luna,Jeffrey C. Thompson,Charu Aggarwal,Erica L. Carpenter,Despina Kontos,Sharyn I. Katz	11
8	Serial Monitoring of Circulating Tumor DNA by Next-Generation Gene Sequencing as a Biomarker of Response and Survival in Patients With Advanced NSCLC Receiving Pembrolizumab-Based Therapy 2021 ·JCO Precision Oncology ·Jeffrey C. Thompson,Erica L. Carpenter,(unknown),(unknown),Austin L. Chien,Katie Quinn,Carin R. Espenschied,Allysia J. Mak,Lesli A. Kiedrowski,Martina I. Lefterova,Rebecca J. Nagy,Sharyn I. Katz,Stephanie S. Yee,Taylor A. Black,Aditi P. Singh,Christine Ciunci,Joshua Bauml,Roger B. Cohen,Corey J. Langer,Charu Aggarwal	62
9	Combining radiomic phenotypes of non-small cell lung cancer with liquid biopsy data may improve prediction of response to EGFR inhibitors 2021 ·Scientific Reports ·Bardia Yousefi,Michael J. LaRiviere,Eric A. Cohen,(unknown),Stephanie S. Yee,Taylor A. Black,Austin L. Chien,Peter B. Noël,Wei‐Ting Hwang,Sharyn I. Katz,Charu Aggarwal,Jeffrey C. Thompson,Erica L. Carpenter,Despina Kontos	24
10	Optimization of Sources of Circulating Cell-Free DNA Variability for Downstream Molecular Analysis 2021 ·Journal of Molecular Diagnostics ·Jacob E. Till,Taylor A. Black,Caren Gentile,(unknown),(unknown),(unknown),Jacquelyn J. Roth,Robyn T. Sussman,Stephanie S. Yee,Mark H. O’Hara,Jeffrey C. Thompson,Charu Aggarwal,Wei‐Ting Hwang,Kojo S.J. Elenitoba‐Johnson,Erica L. Carpenter	9
11	The Role of Imaging in the Management of Suspected or Known COVID-19 Pneumonia. A Multidisciplinary Perspective 2020 ·Annals of the American Thoracic Society ·Leonid Roshkovan,(unknown),Maya Galperin-Aizenberg,(unknown),Rosita M. Shah,(unknown),Scott Simpson,Tessa S. Cook,Arun C. Nachiappan,Friedrich Knollmann,Harold Litt,Benoit Desjardins,Saurabh Kumar Jha,Nova L. Panebianco,Cameron Baston,Jeffrey C. Thompson,Sharyn I. Katz	12
12	Phenotypic and functional analysis of malignant mesothelioma tumor-infiltrating lymphocytes 2019 ·OncoImmunology ·Astero Klampatsa,Shaun O’Brien,Jeffrey C. Thompson,Abhishek Rao,Jason Stadanlick,Marina C. Martinez,Maria Liousia,Edward Cantu,Keith A. Cengel,Edmund K. Moon,Sunil Singhal,Evgeniy Eruslanov,Steven Μ. Albelda	34
13	Neutrophil content predicts lymphocyte depletion and anti-PD1 treatment failure in NSCLC 2019 ·JCI Insight ·Julia Kargl,Xiaodong Zhu,Huajia Zhang,Grace Yang,Travis J. Friesen,(unknown),Dean Y. Maeda,John A. Zebala,Jill McKay-Fleisch,Gavin Meredith,Afshin Mashadi-Hossein,Christina S. Baik,Robert H. Pierce,Mary W. Redman,Jeffrey C. Thompson,Steven Μ. Albelda,Hamid Bolouri,A. McGarry Houghton	127
14	Function of Human Tumor-Infiltrating Lymphocytes in Early-Stage Non–Small Cell Lung Cancer 2019 ·Cancer Immunology Research ·Shaun O’Brien,Astero Klampatsa,Jeffrey C. Thompson,Marina C. Martinez,Wei‐Ting Hwang,(unknown),(unknown),Soyeon Kim,Edward Cantu,Leslie A. Litzky,Sunil Singhal,Evgeniy Eruslanov,Edmund K. Moon,Steven Μ. Albelda	67
15	Gene signatures of tumor inflammation and epithelial-to-mesenchymal transition (EMT) predict responses to immune checkpoint blockade in lung cancer with high accuracy 2019 ·Lung Cancer ·Jeffrey C. Thompson,Wei‐Ting Hwang,Christiana Davis,Charuhas Deshpande,(unknown),Yashoda Rajpurohit,Vinod Krishna,(unknown),Raluca Verona,Matthew V. Lorenzi,Corey J. Langer,Steven Μ. Albelda	93
16	P1.01-64 Impact of STK11 Co-Mutation on Outcomes Following Immunotherapy Among Patients with TP53 and KRAS Mutated Stage IV NSCLC 2018 ·Journal of Thoracic Oncology ·Melina E. Marmarelis,Erin M. Bange,Stephen Bagley,Wei‐Ting Hwang,Yun Yang,Jeffrey C. Thompson,Joshua Bauml,Christine Ciunci,Evan Alley,Jennifer D. Morrissette,Roger B. Cohen,Corey J. Langer,Erica L. Carpenter,Charu Aggarwal	2
17	Radiologic Pseudoprogression during Anti–PD-1 Therapy for Advanced Non–Small Cell Lung Cancer 2018 ·Journal of Thoracic Oncology ·Sharyn I. Katz,Mark M. Hammer,Stephen Bagley,Charu Aggarwal,Joshua Bauml,Jeffrey C. Thompson,Arun C. Nachiappan,Charles B. Simone,Corey J. Langer	75
18	P3.02c-029 Immune-Related Adverse Events and Their Effect on Outcomes in Patients (pts) with Non-Small Cell Lung Cancer (NSCLC) Treated with Nivolumab 2017 ·Journal of Thoracic Oncology ·Shawn Kothari,Stephen Bagley,Charu Aggarwal,Joshua Bauml,Evan Alley,Tracey L. Evans,John A. Kosteva,Christine Ciunci,Jeffrey C. Thompson,Susan Stonehouse-Lee,Victoria Sherry,Elizabeth Gilbert,Beth Eaby‐Sandy,Faith Mutale,Gloria A DiLullo,Roger B. Cohen,Anil Vachani,Corey J. Langer	9
19	P3.02c-028 Outcomes of Nivolumab in Elderly Patients (pts) with Non-Small Cell Lung Cancer (NSCLC) 2017 ·Journal of Thoracic Oncology ·Stephen Bagley,Shawn Kothari,Charu Aggarwal,Joshua Bauml,Evan Alley,Tracey L. Evans,John A. Kosteva,Christine Ciunci,Jeffrey C. Thompson,Susan Stonehouse-Lee,Victoria Sherry,Elizabeth Gilbert,Beth Eaby‐Sandy,Faith Mutale,Gloria A DiLullo,Roger B. Cohen,Anil Vachani,Corey J. Langer	4
20	Use of Circulating Tumor Cell Technology (CELLSEARCH) for the Diagnosis of Malignant Pleural Effusions 2013 ·Annals of the American Thoracic Society ·(unknown),Jeffrey C. Thompson,Gordon H. Yu,Anil Vachani,Bhavesh Vaidya,Chandra Rao,Mark C. Connelly,(unknown),Kay See Tan,Daniel F. Heitjan,Steven Μ. Albelda	19

About Jeffrey C. Thompson

Jeffrey C. Thompson is a scholar working on Oncology, Energy Engineering and Power Technology and Cancer Research, having authored 60 papers that have together received 1.4k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (18 papers), Cancer Immunotherapy and Biomarkers (15 papers) and Cancer Genomics and Diagnostics (14 papers). The work is most often cited by research in Oncology (923 citations), Cancer Research (303 citations) and Pulmonary and Respiratory Medicine (582 citations). Jeffrey C. Thompson has collaborated with scholars based in United States, United Kingdom and Austria. Frequent co-authors include Charu Aggarwal, Corey J. Langer, Joshua Bauml, Roger B. Cohen, Robert Broadwater, Christine Ciunci, Stephen Bagley, Erica L. Carpenter, Steven Μ. Albelda and Wei‐Ting Hwang. Their work appears in journals such as Journal of Clinical Oncology, Blood and Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact